-------------------------------
MB APPROVAL
-------------------------------
OMB Number: 3235-0060
-------------------------------
Expires: March 31, 2006
-------------------------------
Estimated average burden
Hours per response: 2.64
-------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 28, 2004
-------------
Celsion Corporation
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14242 52-1256615
---------------------------- ----------------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
10220-L Old Columbia Road, Columbia, Maryland 21046-2364
---------------------------------------------------------
(Address of principal executive office) (Zip Code)
Registrant's telephone number, including area code: (410) 290-5390
---------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS
(A) On May 28, 2004, Celsion Corporation (the "Registrant") announced, by
way of a press release, that it had become aware that its common stock
was listed for trading on the Berlin-Breman Stock Exchange and that it
had requested delisting from that Exchange. A copy of the press release
is attached as Exhibit 99.1 to this Report on Form 8-K.
(B) On June 1, 2004, the Registrant announced, by way of a press release,
that it had filed with the Food and Drug Administration (the "FDA") its
response to a warning letter issued to it by the FDA on May 7, 2004. A
copy of the press release is attached as Exhibit 99.2 to this Report on
Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CELSION CORPORATION
Date: June 2, 2004 By: /s/ Augustine Y. Cheung
------------ ------------------------------------
President and Chief Executive Officer
Exhibit Index
Exhibit No. Description
99.1 Registrant's press release dated May 28, 2004,
regarding listing of its common stock on the
Berlin-Breman Stock Exchange and request for
delisting of the common stock.
99.2 Registrant's press release dated June 1, 2004,
regarding filing, by Registrant, of its response to a
warning letter received by it from the Food and Drug
Administration on May 7, 2004.